Drug Approval | August 16, 2023
Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations
The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).
Newcastle University’s Dr Srikanth Ramaswamy has been announced as one of six new Fellows selected for the 2023 Lister prize
The survey findings for Delhi-NCR revealed that speech sound disorders exhibit higher prevalence rates in the 6-12 years age group
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023
Krsnaa Diagnostics has reported total income of Rs. 143.80 crores during the period ended June 30, 2023
Panacea Biotec has reported total income of Rs. 135.27 crores during the period ended June 30, 2023
Subscribe To Our Newsletter & Stay Updated
